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Abstract
The surrogate light chain (SLC) consists of the polypeptides k5 and, in the mouse, either VpreB1 or
VpreB2. SLC associates with BILL-Cadherin and other glycoproteins to form the pro-B cell receptor
(pro-BCR) at the pre-BI cell stage, and with the immunoglobulin l heavy chain to form the pre-BCR at
the pre-BII cell stage. The function of the pro-BCR, if any, is unknown, whereas the pre-BCR is crucial
for proliferative expansion of pre-BII cells. To shed light on the functional properties of VpreB1 and
VpreB2 in vivo, mice with either one or two VpreB1, or one or two VpreB2, alleles have been
investigated. We show that B cell development in mice with two VpreB1 alleles is indistinguishable
from that of normal mice. In contrast, mice with two VpreB2 alleles show an ~1.6-fold increase in
pre-BI and a 35% decrease in pre-BII cell numbers, while mice with only one VpreB2 allele show
a reduction in B cell development manifested in a 2-fold enrichment in pre-BI cells and a 75%
reduction in pre-BII cells. However, such a gene dosage effect is not observed for VpreB1. Our results
suggest that the difference between VpreB1- and VpreB2-deficient mice is due to lower VpreB2
protein expression, thus limiting the formation of pre-BCRs and thereby the number of large, cycling
pre-BII cells.
Introduction
The surrogate light chain (SLC), encoded by the VpreB and k5
genes, is specifically expressed in precursor B cells (1, 2).
During early B cell development, SLC is initially expressed
in pre-BI (DJH-recombined) cells, where it associates with
BILL-Cadherin and other glycoproteins in a complex termed
the pro-B cell receptor (pro-BCR) (3). At the following, large
pre-BII (VDJH-recombined) cell stage, SLC together with Ig l
heavy (lH) chain forms the pre-BCR (4, 5). Pre-BCR
expression has been proposed to act as a checkpoint to
monitor expression of a functional lH chain, developmental
progression and clonal expansion resulting later in a broad Ig
repertoire (6).
In contrast to humans who only have one VpreB gene (7),
mice have two, VpreB1 and VpreB2 (1, 8). The mouse VpreB
genes, located on chromosome 16, are 97% identical at the
nucleotide level, resulting in a difference of four amino acids in
the corresponding protein. VpreB1 is located ~4.5 kb
upstream of k5 while VpreB2 is situated ~1 Mb downstream
and in the opposite transcriptional orientation. Both VpreB1
and VpreB2 can associate with k5 to form the SLC (9, 10).
Mice lacking either the entire SLC (SL/) or its components,
i.e. k5T and VpreB1/VpreB2/ mice, have a mild enrich-
ment in the number of pre-BI cells and greatly reduced
numbers of pre-BII cells (11–13). The enrichment of pre-BI
cells is currently not understood but may be explained for
example by an unknown function of the pro-BCR, because the
lack of BILL-Cadherin also results in an enrichment of pro-/pre-
BI cells (14). The reduction in pre-BII cells is explained by the
essential role of the pre-BCR for proliferative expansion of
these cells (15–17). The amount of SLC that is required to
generate normal-sized pre-BI and pre-BII cell populations and
consequently normal B cell numbers is currently unknown.
B cell development is unaffected in haplo-deficient SLC mice,
i.e. k5+/, VpreB1+/VpreB2+/ and SL+/ (11–13), which
suggests that half the normal amount of protein is sufficient,
provided that the expression from one allele results in a 50%
reduction in protein levels.
We have previously shown that VpreB1 deficiency results in
a partial impairment of B cell development (18). Here we de-
monstrate, somewhat unexpectedly, that B cell development
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is normal in VpreB2-deficient mice. In pursuing the reason for
this discrepancy we have also analyzed mice carrying either
only one functional VpreB1 or one functional VpreB2 allele.
Methods
Generation of VpreB2-deficient mice
The generation and analysis of VpreB1/VpreB2/ mice
have been described previously (12). Briefly, the VpreB2 gene
was replaced with the hygromycin resistance gene by
homologous integration in ES cells, already heterozygous for
VpreB1 deficiency. As the two genes are located on the same
chromosome, this resulted in 40% of the clones having
undergone homologous recombination on the same chromo-
some as the VpreB1-targeting event and the other 60% on the
non-targeted chromosome. Thus, this resulted in both single-
and double-deficient mice. The VpreB2 heterozygous mutant
mice were intercrossed to establish VpreB2/ mice. Two (out
of three) VpreB2/mouse lines were analyzed in detail and as
both phenotypes were identical the results of only one line are
shown. These initial analyses were carried out on mice of
mixed genetic background. The VpreB2, VpreB1 and VpreB1/
VpreB2 double-deficient mice were then backcrossed for >10
generations onto the C57BL/6 background. VpreB1/
VpreB2/ were thereafter crossed with either VpreB1/ or
VpreB2/ mice to generate offspring with either one VpreB1
or one VpreB2 allele. Mice were bred in the Babraham
Institute’s animal facility under home office project licenses 80/
1501, 1143 and 1763. Gene targeted mice were genotyped by
PCR as previously described (12, 18) and analyzed at 3–8
weeks of age.
FACS analysis of lymphoid organs
Bone marrow (BM) and spleen cell suspensions were pre-
pared and stained with antibodies as described previously
(12) except anti-Ki-67 (clone B56) and PE-labeled anti-CD25
(clone 7D4) (BD PharMingen, Heidelberg, Germany). To
investigate proliferation, BM B220+CD25+ cells were sorted
on a FACSAria (Becton Dickinson), fixed in ethanol, stained
with propidium iodide (Sigma) in the presence of RNaseA
(Sigma) and analyzed using CellQuest (Becton Dickinson), as
previously described (19).
For enzymatic amplification staining of cell surface mol-
ecules, ex vivo BM cells were incubated at 37C for 1 h followed
by a B cell-enrichment step using anti-CD19 magnetic beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were
thereafter stained with biotinylated antibodies recognizing k5
(LM34), VpreB1/VpreB2 (VP245) (3) or the pre-BCR (SL156)
(20). The enzymatic amplification was performed using a kit for
biotinylated primary antibodies (EAS-B, Flow-Amp, Cleveland,
USA), according to the manufacturer’s instructions. In some
instances markers for additional cell-surface molecules were
included in the last step of the amplification procedure.
For intracellular antibody staining, BM cells from 2 to 5 mice
were pooled, enriched for B-lineage cells using anti-CD19
magnetic beads and stained for the expression of cell surface
markers as described above. After fixation with formaldehyde
the cells were permeabilized and stained intracellularly, accord-
ing to the manufacturer’s protocol (Fix & Perm, Cell Per-
meabilization Kit, Caltag Laboratories, Burlingame, CA, USA).
The biotinylated antibodies used were LM34 and VP245 or an
isotype control, biotinylated rat IgG2a (clone R35-95, BD
PharMingen), as well as polyclonal FITC-labeled goat anti-
mouse IgM or goat IgG used as an isotype control (Southern
Biotechnology Associates, Inc., Birmingham, AL, USA).
Immunofluorescence microscopy
For immunofluorescence microscopy, BM cells from VpreB1/,
VpreB2/ and VpreB1/VpreB2/ mice were cultured on
irradiated stromal cells in the presence of IL-7 for 7 days. Cells
were fixed onto coverslips pre-coated with 0.01% poly-L-lysine
solution and stained with LM34 or VP245, followed by FITC-
conjugated goat anti-rat IgG (Jackson ImmunoResearch,
Baltimore, MD, USA). Coverslips were analyzed (363 magni-
fication) under a Zeiss Axiophot fluorescent microscope (Carl
Zeiss Ltd, Jena, UK). Using this protocol, both intracellular and
surface antigens are stained.
Reverse transcription–PCR analysis
BM cells were enriched for CD19-positive cells using magnetic
beads and sorted for CD19+c-kit+ cells. Total RNA was
prepared from 2 3 105 sorted cells using RNA-Bee (AMS
Biotechnology, Oxon, UK) followed by cDNA synthesis using
random primers (Life Technologies). The cDNAs were ana-
lyzed by PCR using primers specific for VpreB1, VpreB2, k5
and HGPRT or with primers that detect both VpreB1 and
VpreB2 (11).
Results
Normal B cell development in VpreB2-deficient mice
To investigate whether the absence of VpreB2 resulted in any
effect on B cell development, VpreB2-deficient (VpreB2/)
mice were generated (12). Successful targeting of the VpreB2
gene was confirmed by Southern blotting (12) and by the
fact that mRNA encoding VpreB2 was not detected in
homozygous VpreB2-deficient mice, whereas mRNA from
both VpreB1 and k5 were detected (Supplementary Figure 1,
available at International Immunology Online). After confirming
that targeting of the VpreB2 gene resulted in a loss of VpreB2
but not VpreB1 and k5, BM B cell development was
investigated for possible lesions. There was no difference
between VpreB2+/+, VpreB2+/ and VpreB2/ mice in the
number of pre-BI (B220+CD19+c-kit+), pre-BII (B220+CD25+)
and immature/mature (B220+IgM+IgD+/) B cells (Table 1 and
data not shown). Although there was no obvious effect on BM
B cell development in VpreB2/ mice, it could be that there
was some effect on the peripheral B cell pool. However, similar
numbers of IgM+ and IgD+ B cells were observed in the spleen
of VpreB2+/ and VpreB2/ mice (Table 1). Analysis of
peritoneal B cells revealed that the numbers of B-1 and B-2
B cells were also similar in these mice (data not shown).
Furthermore, serum IgM levels were normal as were the re-
sponses to T-cell-dependent (NP-OVA) and T-cell-independent
(NP-Ficoll) antigens (data not shown). These results demon-
strate that BM B cell development in VpreB2-deficient mice is
normal, resulting in the generation of normal numbers of
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peripheral B-1 and B-2 B cells. Furthermore, these B cells
are functional, as reflected in normal serum IgM levels as
well as normal T cell-dependent and -independent immune
responses.
Comparison of VpreB2/ and VpreB1/ mice
The above results demonstrate that the absence of VpreB2
has no effect on BM B cell development, which is in contrast to
mice lacking VpreB1 (VpreB1/) (18), in which there is an
impairment at the transition from the pre-BI to the pre-BII cell
stage. This difference was confirmed after backcrossing the
two lines onto the C57BL/6 background (Fig. 1A). In the BM,
a 1.6-fold enrichment of pro-/pre-BI (B220+c-kit+) cells was
observed in VpreB1/ compared with VpreB2/ mice. At the
following pre-BII stage (B220+CD25+), cell numbers were
reduced by ~35% resulting in fewer (reduced by ~40%) IgM+
cells in VpreB1/ compared with VpreB2/ mice. Thus, in
the presence of only VpreB1 B cell development is normal,
whereas in mice expressing only VpreB2 it is not.
The proliferation of pre-BII cells is unaffected in mice
expressing only VpreB2
The lack of either VpreB1 and VpreB2, k5 or the entire SLC
results in a 2- to 3-fold enrichment of pre-BI and a 20- to 40-
fold reduction of pre-BII cells (11–13), the latter ascribed to
a lack of pre-BII cell proliferation (15–17). Because the
deficiency of VpreB1 also resulted in an enriched pre-BI and
a mildly decreased pre-BII cell population, we reasoned that
this may be the result of an effect on pre-BII cell proliferative
expansion. Based on forward scatter analysis, the pre-BII
population can be divided into large cycling and small resting
cells in a ratio of ~20–25% large to 75–80% small cells (21).
This ratio changes to ~40:60% in VpreB1/VpreB2 double-
deficient mice but was previously found to be unaffected in
VpreB1/ mice (12, 18). A similar analysis performed on the
backcrossed VpreB1/ as well as VpreB2/ mice showed
that the ratio of large to small pre-BII cells in the two genotypes
was normal (data not shown). To further investigate pro-
liferation, levels of the proliferation-associated antigen, Ki-67,
and the proportion of cells in S/G2/M of the cell cycle were
analyzed. Independent of genotype, the vast majority of pre-
BII cells expressed Ki-67 (Fig. 1B). Given that large cycling
pre-BII cells are by definition Ki-67+, this indicates that the
majority of small resting pre-BII cells must also be positive.
Thus, recently cycling cells retain expression of Ki-67, in
contrast to the majority of re-circulating, mature B cells which
are Ki-67 negative (data not shown). Furthermore, determina-
tion of the proportion of pre-BII cells in S/G2/M phase of the cell
cycle revealed a similar percentage (12–13%) in both
VpreB1/ and VpreB2/ mice (Fig. 1B). Thus, these data
would suggest that the proportion of cycling pre-BII cells is
similar, regardless of whether they express either VpreB1 or
VpreB2. Because the total number of pre-BII cells is reduced
in VpreB1-deficient mice (Fig. 1A), there is a consequent
reduction in the number of cycling pre-BII cells.
VpreB2 mRNA levels are lower than those of VpreB1
The above results show that VpreB1 and VpreB2 differ in their
ability to support early BM B cell development. There are
several explanations that could account for this difference. For
instance, different lH chains differ in their ability to pair with
SLC (22) and some of these lH chains are able to associate
with VpreB in the absence of k5. However, we were unable to
find any difference between the VpreB1 and VpreB2 poly-
peptides in their ability to pair with different lH chains (22).
Another possibility could be an effect on the level of SLC,
due to a change in k5 levels. In this scenario, the neomycin
cassette, which replaces the deleted VpreB1 gene, might
affect the expression of the neighboring k5 gene. However, the
k5 mRNA steady-state level in both total BM and sorted pre-BI
(CD19+c-kit+) cells from VpreB1/ and VpreB2/ mice was
similar as determined by semi-quantitative reverse transcrip-
tion (RT)-PCR (Fig. 2 and data not shown). Thus, the difference
Table 1. Cell populations in VpreB2/ mice
+/ /
BMa
Nucleated cells 32.3 6 7.3 33.4 6 4.0
B220+ 7.1 6 2.1 7.9 6 1.7
CD19+ 6.9 6 1.9 7.6 6 1.6
B220+c-kit+ 0.5 6 0.1 0.6 6 0.2
B220+CD25+ 4.6 6 1.9 4.9 6 1.2
B220+IgM+ 1.8 6 0.5 1.8 6 0.4
Spleenb
Nucleated cells 161.0 6 58.0 173.0 6 54.0
B220+ 49.0 6 7.4 48.0 6 13.8
B220+IgM+ 43.0 6 5.4 43.0 6 12.1
B220+IgD+ 34.0 6 4.8 36.0 6 13.5
The mean and SD of absolute cell numbers (3106) are shown (two
femurs for BM).
aN ¼ 8. bN ¼ 3. Mice were 18–21 days old.
Table 2. VpreB gene dosage effect on BM cell populations
VpreB1 +/ +/ / /
VpreB2 +/a / +/ /
Lymphocytes 10.57 6 0.80 10.10 6 3.12 7.96 6 2.46 7.16 6 1.53
B220+CD19c-kit+ n.d. 0.016 6 0.008 0.014 6 0.005 0.01 6 0
B220+c-kit+ 0.36 6 0.06 0.33 6 0.14 0.71 6 0.22 0.67 6 0.22
B220+CD25+ 3.30 6 0.61 3.60 6 1.36 0.94 6 0.29 0.07 6 0.02
B220+IgM+ 1.70 6 0.24 1.33 6 0.42 0.31 6 0.12 0.04 6 0.01
The mean and SD of absolute cell numbers (3106) from one femur are shown (6–10 mice per genotype). Mice were 3–4 weeks old. n.d., not done.
aMice were 8 weeks old.
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in phenotype between mice expressing either VpreB1 or
VpreB2 is not due to an effect on k5 mRNA levels.
Since VpreB2 is located 1 Mb downstream of VpreB1, it is
unlikely that targeting of VpreB1 would have an effect on the
expression of VpreB2. However, several lines of evidence
suggest that VpreB1 and VpreB2 are both expressed albeit at
different levels. Firstly, in a panel of 10 pre-B cell lines all ex-
press both VpreB genes (10), although the level of VpreB2
may be lower than that of VpreB1 (23). Secondly, single-cell
RT-PCR analysis of B220+c-kit+ cells showed that all express
VpreB1 and k5, whereas VpreB2 mRNA was detectable in
~30% of these cells. However, we suggested this as a mini-
mum figure on account of assay sensitivity limits (10). Thirdly,
the activity of the VpreB2 promoter is ~3-fold lower compared
with that of the VpreB1 (10). Taken together, this suggested
that VpreB2 is expressed in all pre-BI cells, but at a lower level
Fig. 1. Comparative FACS analysis of BM cells from VpreB2/ and VpreB1/ mice. (A) Analysis of BM cell populations after staining for the
indicated markers. Viable cells within the lymphocyte gate are shown. Numbers indicate the percentage of cells within the quadrant. The mean
absolute numbers (3106) for 5–8 mice (3 weeks) of each genotype were for VpreB2/ mice: lymphocytes, 8.6 6 1.3; B220+c-kit+, 0.36 6 0.13;
B220+CD25+, 2.06 0.70; B220+IgM+, 0.76 0.16; and for VpreB1/ mice: lymphocytes, 8.06 2.2; B220+c-kit+, 0.566 0.22; B220+CD25+, 1.326
0.60; B220+IgM+, 0.46 0.21. (B) Analysis of pre-BII cell proliferation. Cells were stained for indicated markers. Middle panels, expression levels of
cytoplasmic l (cl) and nuclear proliferation antigen Ki-67 after gating on pre-BII (B220+CD25+) cells. The percentages of cells in the relevant
quadrants are shown. Right panels, DNA content in nuclei after sorting B220+CD25+ cells. The marker indicates the percentage of cells in S/G2/M
phases of the cell cycle determined using propidium idodide.
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than VpreB1, although it was possible that only a propor-
tion of cells express VpreB2. We therefore set out to inves-
tigate VpreB1 and VpreB2 mRNA levels using a primer pair
which is equally efficient in detecting both. For this pre-BI cell
(CD19+c-kit+) RNA from VpreB1/ and VpreB2/ mice was
analyzed. As shown in Fig. 2, the amount of VpreB2 mRNA is
about one-third that of VpreB1 (normalized against HGPRT).
Thus, in pre-BI cells from normal mice, VpreB2 mRNA levels
correspond to ~25% of total VpreB levels.
VpreB2 protein levels are lower than those of VpreB1 on
the surface of pre-BI cells
To investigate whether the low VpreB2 mRNA level was
reflected in protein level, and if so, whether this was due to
an overall lower VpreB2 level or only a fraction of cells
expressing VpreB2, ex vivo BM pre-BI (B220+CD19+c-kit+)
cells from VpreB1/ and VpreB2/ mice were analyzed for
surface VpreB and k5 protein expression. As shown in
Fig. 3(A) (top panel), in VpreB2/ mice, VpreB1 levels varied
greatly between cells, with fluorescence levels spanning
almost two orders of magnitude. Furthermore, two populations
were observed, one with high and the other with low levels.
Similarly, two VpreB2-expressing cell populations were ob-
served in VpreB1/ mice, one expressing low and the other
higher levels (middle panel). However, the VpreB2 ‘high’ levels
were lower than those of the VpreB1 ‘high’-expressing
population, whereas those of the low-expressing populations
were similar (bottom panel). Gating on the positive cells
showed that 81% expressed VpreB1 and 59% VpreB2. Two
sub-populations were also observed in terms of k5, with
a similar proportion of VpreB1- and k5-expressing (~80%)
cells, whereas there were more cells expressing k5 (77%) than
VpreB2 (59%). In addition, independent of genotype, the
mean fluorescence intensity (MFI) was higher for k5 than
VpreB (126 versus 83 and 58 versus 36 in VpreB2/ and
VpreB1/ mice, respectively). This may indicate that k5 is
expressed in a protein complex lacking VpreB which would be
supported by a previous observation that k5 is detected on the
surface of pre-B cells from VpreB1/VpreB2/ mice (24).
Nevertheless, this shows that pre-BI cells can be divided into
two sub-populations in terms of surface SLC expression,
whether they express VpreB1 or VpreB2, although when it
comes to VpreB2, the level on the ‘high’-expressing sub-
population is lower compared with VpreB1.
VpreB2 and VpreB1 protein levels are similar on the
surface of pre-BII cells
The pre-BCR is expressed at very low levels on large pre-BII
(CD19+CD25+) cells, while small pre-BII cells do not express
SLC, i.e. are pre-BCR negative (25, 26). In agreement with this,
analysis of pre-BII cells from VpreB2/ mice confirmed that
the surface levels of pre-BCR, as well as VpreB1 and k5, were
very low (Fig. 3B). In VpreB1/ mice, the levels of pre-BCR,
VpreB2 and k5 were also very low, although it was not obvious
from this analysis whether there was a difference between
cells expressing either VpreB1 or VpreB2. Nevertheless, at the
pre-BII cell stage, there is no distinct difference between
VpreB1 and VpreB2, although this may be due to poor
resolution since the SLC levels are much lower on pre-BII
compared with pre-BI cells. Alternatively, VpreB1 and VpreB2
expression levels are similar at the large pre-BII stage.
Lower surface/intracellular levels of VpreB2 in in vitro
cultured pre-BI cells
Because the surface staining suggested similar levels of
VpreB1 and VpreB2 in pre-BII but not in pre-BI cells, it was
important to determine whether the low VpreB2 levels in pre-BI
cells were due to a sub-population not expressing VpreB2 or
alternatively to overall lower VpreB2 levels. We therefore
cultured BM cells from the mutant mice short term (1 week)
in vitro (27). The cells were then analyzed by immunofluo-
rescence microscopy after staining for both surface and
intracellular VpreB and k5. As shown in Fig. 4 (in color as
Supplementary Figure 2, available at International Immun-
ology Online), the vast majority of cells stained positive for
VpreB2 although expressing lower levels compared with
VpreB1. The lack of VpreB signal in pre-BI cells from
VpreB1/VpreB2/ mice, cultured in parallel, demonstrates
that the low level of VpreB2 in pre-BI cells from VpreB1/
mice is the result of specific staining. The cells from the
double-deficient mice stained, as expected, positive for k5.
This shows therefore that, in pre-BI cells, VpreB1 is expressed
at higher levels than VpreB2.
VpreB protein levels in mice with either one VpreB1 or
one VpreB2 allele
To investigate the levels of VpreB1 and VpreB2 further, BM
pre-BI and pre-BII cells from VpreB1/ and VpreB2/ mice
were analyzed for intracellular levels of VpreB and k5 (Fig. 5).
In contrast to surface expression and because the bulk of
VpreB2-expressing cells shifted compared with that of the
negative control, not only VpreB1 but also VpreB2 was found
to be expressed in the majority of pre-BI cells. A division into
two sub-populations was not obvious. However, the intracel-
lular levels of VpreB2 were lower than those of VpreB1.
Therefore, the intracellular VpreB1 and k5 levels seemed to
better reflect that of the mRNA levels. Thus, the majority of
pre-BI cells express VpreB2 but at a lower level than that of
VpreB1.
The results from pre-BI cells suggested a correlation be-
tween VpreB1 and VpreB2 mRNA and protein levels, implying
a dosage effect between the two genes. To investigate
whether there is also a gene dosage effect, VpreB1/VpreB2
double-deficient (VpreB1/VpreB2/) mice were crossed
Fig. 2. Semi-quantitative RT-PCR. cDNA from BM pre-BI (CD19+
c-kit+) cells from mice of the indicated genotypes (C57BL/6; B6) was
amplified for HGPRT, k5 and VpreB (using a primer pair amplifying
VpreB1 and VpreB2). Five-fold serial cDNA dilutions were used.
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Fig. 3. Comparative FACS analysis of surface expression levels of VpreB, k5 and pre-BCR in VpreB2/ and VpreB1/ mice. BM cells were
enriched for CD19-positive cells and stained for the indicated markers. Cells were gated (shown for VpreB2/) as (A) pre-BI (B220+c-kit+) or
(B) pre-BII (B220+CD25+) cells. Bold lines, VpreB1 protein (VpreB2/ mice); dotted lines, VpreB2 protein (VpreB1/ mice); filled histograms,
isotype controls. Representative plots from at least three experiments performed on individual mice are shown. Superscript e indicates
enzymatically enhanced stains.
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with VpreB2/ and VpreB1/ mice, resulting in mice with
either one VpreB1 (VpreB1+/VpreB2/) or one VpreB2
(VpreB1/VpreB2+/) allele. Initially, BM pre-BI cells from
mice with two (VpreB1+/+VpreB2/) or one (VpreB1+/
VpreB2/) VpreB1 allele were compared for intracellular
levels of VpreB and k5 in combination with lH chain. As shown
in Fig. 5, no obvious gene dosage effect was observed in
terms of VpreB1 expression levels (MFI 26 and 27, respect-
ively). In contrast, a gene dosage effect was observed for
VpreB2: mice with two VpreB2 alleles (VpreB1/VpreB2+/+)
Fig. 4. Comparative immunofluorescence microscopy of VpreB1 and
VpreB2 protein levels in in vitro cultured pre-BI cells. BM cells from
VpreB1/, VpreB2/ and VpreB1/VpreB2/ mice were cultured
on irradiated stromal cells in the presence of IL-7. After 7 days cells
were analyzed for a combination of intracellular and surface
expression of k5 or VpreB using immunofluorescence microscopy.
Representative figures from at least three experiments performed on
individual mice are shown.
Fig. 5. Comparative FACS analysis of intracellular expression levels of
VpreB, k5 and lH chain. BM preparations of the indicated genotypes
were enriched for CD19-positive cells and stained for surface,
followed by intracellular, expression of the indicated markers. Cells
were gated as pre-BI (B220+c-kit+) and large pre-BII (large
B220+CD25+) cells. Because small pre-BII (small B220+CD25+) cells
do not express VpreB and k5, they were used as negative controls
(gray histograms, dot plot in last row). Numbers in histograms
represent the mean fluorescence levels; gray boxes represent
negative control. In dot plots the percentage of cells in the relevant
quadrants are shown. Representative plots from two experiments,
each using pooled cells from 2 to 6 mice, are shown.
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showing higher expression levels (MFI 14 versus 9) than those
with one (VpreB1/VpreB2+/). Although the levels were very
low in the latter, because most of the population shifted as
compared with the negative control, this suggested that the
majority of cells did express VpreB2. Furthermore, within each
genotype, the levels of VpreB, regardless of it being VpreB1 or
VpreB2, were similar when comparing lH-positive or -negative
cells (Fig. 4).
Thereafter the intracellular levels of VpreB and k5, in
combination with lH chain, were analyzed in large pre-BII
cells (Fig. 5). Since small pre-BII cells do not express SLC,
these cells from the same individual stain were used as
negative controls. As expected, the levels of both VpreB and
k5 were low at the large pre-BII stage. Somewhat unexpect-
edly, though in agreement with the surface expression (Fig. 3),
there was no obvious difference in VpreB levels when
comparing mice expressing VpreB1 or VpreB2 or when
comparing mice with either one or two alleles (Fig. 5). In
accordance with this, the levels of k5 were also very similar
independent of genotype. Taken together, these data show
that the number of VpreB2 but not VpreB1 alleles affects
VpreB protein levels at the pre-BI cell stage. However, at the
large pre-BII stage, cells express similar levels of VpreB,
irrespective of whether either VpreB1 or VpreB2, or either one
or two alleles are present.
B cell development in mice with only one VpreB1 or one
VpreB2 allele
As we show above, BM B cell numbers are normal in mice with
two VpreB1 but not in mice with two VpreB2 alleles (Fig. 1 and
Table 1). This discrepancy may be due to lower VpreB2 levels
resulting in lower surface SLC expression at the pre-BI cell
stage. If a lower level of VpreB protein ultimately results in the
production of fewer BM B cells, we would also predict, based
on the above FACS analyses (Fig. 5), an effect in mice with
only one VpreB2 but not in mice with only one VpreB1 allele. To
investigate this, the size of the different BM B cell populations
was determined in the various mouse lines. As B cell
development is normal in VpreB1/VpreB2 haplo-deficient
(VpreB1+/VpreB2+/) mice, they were used as controls (12).
The sizes of the pre-BI and pre-BII cell populations were similar
in VpreB1/VpreB2 heterozygous-deficient mice and mice with
one VpreB1 allele (VpreB1+/VpreB2/). The number of
B220+IgM+ cells in the former was slightly higher due to more
re-circulating B cells, in agreement with these mice being older
(8 weeks compared with 3–4 weeks). Nevertheless, the
presence of only one VpreB1 allele results in normal BM B
cell development. In contrast, in mice with only one VpreB2
allele (VpreB1/VpreB2+/), an ~2-fold enrichment in pre-BI,
an ~75% decrease in pre-BII and a similar reduction in the
number of B220+IgM+ cells was observed compared with mice
with only one VpreB1 allele. The effect on the pre-BI and pre-BII
cell populations is therefore more pronounced in mice with one
as compared with two VpreB2 alleles. Even so, in VpreB1/
VpreB2+/ mice, the ratio of large to small pre-BII cells was
normal and ~13% of cells at the pre-BII stage were found to
be in S/G2/M phase of the cell cycle (data not shown), i.e. a
proportion similar to those observed for mice with either two
VpreB1 or VpreB2 alleles (Fig. 1B). Taken together, these
data show that only one VpreB1 allele is still capable of
allowing normal BM B cell development whereas neither one
nor two VpreB2 alleles can do so.
Discussion
Here we demonstrate that BM B cell development is normal
in mice carrying at least one functional VpreB1 allele. In con-
trast, the production of BM B cells is reduced in mice with only
two and, even more so, in mice with only one VpreB2 allele.
Our results suggest that the difference between VpreB1
and VpreB2 is due to unequal expression levels rather than
to the proteins themselves. Thus, VpreB2 mRNA levels are ap-
proximately one-third of those of VpreB1 resulting in lower
protein levels and, at the pre-BI cell stage, lower surface SLC
levels. Thus, these data suggest that the level of SLC is critical
for normal B cell development.
The results described herein suggest that VpreB2 is
expressed in the majority of pre-BI cells but at a lower level
than VpreB1. This is supported by our previous observation
that all pre-B cell lines analyzed so far express both VpreB
genes (10), possibly at different levels (23). However, these
data seem to contradict those of our previously reported
single-cell RT-PCR analyses in which VpreB2 was only
detectable in about a third of those pre-BI cells transcribing
VpreB1 (10). The present results suggest that this discrepancy
can be explained by overall lower VpreB2 compared with
VpreB1 mRNA levels. This is further supported by our
observation that in the single-cell RT-PCR analyses, dilution
of the cDNA often abolished the VpreB2 but not VpreB1 signal
(10). Furthermore, if VpreB2 is only expressed in a third of
pre-BI cells, we would have expected the FACS analyses to
reveal two distinct populations, one with VpreB2 high and one
with undetectable levels. In terms of surface expression, we
observed two populations, although we suggest that both
populations are positive, one expressing high and the other
low levels. We base this on the observation that two popu-
lations were also observed for VpreB1, which is transcribed in
all pre-BI cells (10), and because the low-expressing VpreB1
and VpreB2 sub-populations overlapped. Furthermore, if we
consider the intracellular staining patterns, these suggest that
the VpreB2 levels are overall lower than those of VpreB1. It
may therefore be that VpreB2 is not only expressed at lower
levels than VpreB1 but also that the single-cell RT-PCR assay
was less sensitive for VpreB2 than for VpreB1. We propose
therefore that, under normal circumstances, the majority of
pre-BI cells express both VpreB1 and VpreB2.
Lower levels of VpreB2 mRNA may be the result of a lower
transcription rate due to the regulatory regions of VpreB1 and
VpreB2 not being equally efficient. While the ~350 bp
immediately 59 of the coding sequences are 97% identical at
the nucleotide level, this region of the VpreB2 gene is ~3-fold
less active in transient transfection assays (10). Another
explanation may be the physical location of VpreB2, which is
located 1 Mb downstream of the VpreB1 and k5 genes.
Although all three genes have their own promoter and
enhancer elements (28), they may still be co-regulated by
a locus control region (LCR) located just downstream of k5
(29). If this LCR also acts on VpreB2, it may be less efficient
due to its being further away, resulting in a lower rate of
transcription. Alternatively, it may also be a combination of the
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two, since the LCR seems to act in concert with the individual
promoter/enhancer regions (29).
The VpreB1 and VpreB2 proteins differ in four amino acids
with one located in the leader sequence, one in the unique
non-Ig domain and the other two in the IgV-domain-like region
(1, 30). However, this structural difference does not appear to
bias the selection of different repertoires of VH-, DH- or JH-
containing lH chains (22). Therefore, this supports our
conclusion that the functional difference between VpreB1
and VpreB2 is due to unequal expression levels rather than to
the proteins themselves. In mice expressing only VpreB2,
VpreB mRNA levels are ~25% those of normal, resulting in
lower amounts of VpreB protein and consequently surface
SLC expression at the pre-BI cell stage. However, somewhat
surprisingly, at the pre-BII cell stage SLC expression levels are
similar independent of which and how many VpreB alleles are
expressed. Based on these results, we hypothesize that
a pre-BI cell is only ‘allowed’ to become a large pre-BII cell if it
expresses a certain threshold level of SLC and, consequently,
pre-BCR. In mice, which express only VpreB2, and even more
so in mice with only one functional VpreB2 allele, just
a proportion of pre-BI cells reach this threshold level. Because
of this, fewer cells enter the proliferating large pre-BII cell
compartment resulting in fewer pre-BII and, consequently,
fewer immature B cells. Thus, the SLC level at the pre-BI cell
stage determines the progression from the pre-BI to the
pre-BII stage, ensuring that the cells that enter the pre-BII cell
compartment express sufficient levels of pre-BCR to pro-
liferate normally.
Supplementary data
Supplementary data are available at International Immunology
Online.
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